反応式
[Cl:1][C:2]1[N:7]=[CH:6][C:5]2[CH:8]=[N:9][N:10]([C:11]3[CH:16]=[CH:15][CH:14]=[C:13](F)[N:12]=3)[C:4]=2[CH:3]=1.[NH:18]1[CH2:23][CH2:22][CH2:21][C@H:20]([NH:24][C:25](=[O:31])[O:26][C:27]([CH3:30])([CH3:29])[CH3:28])[CH2:19]1.CN1CCOCC1.O>CN1CCCC1=O>[Cl:1][C:2]1[N:7]=[CH:6][C:5]2[CH:8]=[N:9][N:10]([C:11]3[N:12]=[C:13]([N:18]4[CH2:23][CH2:22][CH2:21][C@H:20]([NH:24][C:25](=[O:31])[O:26][C:27]([CH3:29])([CH3:28])[CH3:30])[CH2:19]4)[CH:14]=[CH:15][CH:16]=3)[C:4]=2[CH:3]=1参加物
6
反応物 4
生成物 1
試薬・触媒・溶媒 1
反応条件
- 温度
- 100 °C
実験手順
A mixture of 6-chloro-1-(6-fluoro-2-pyridyl)pyrazolo[4,3-c]pyridine (2.998 mmol; 745.3 mg), tert-butyl N-[(3S)-3-piperidyl]carbamate (4.496 mmol; 900.5 mg), and N-Methylmorpholine (8.993 mmol; 919 mg; 0.999 mL) in 1-methyl-2-pyrrolidinone (10 mL) in a sealed pressure vial was heated at 100° C. overnight. The mixture was poured into water. The precipitate was collect by filtration, then purified on silica eluted with 0 to 40% EtOAc in Heptane to afford tert-butyl N-[(3S)-1-[6-(6-chloropyrazolo[4,3-c]pyridin-1-yl)-2-pyridyl]-3-piperidyl]carbamate (1.0738 g, 84%).
後処理
- filtrationThe precipitate was collect by filtration
- custompurified on silica
- washeluted with 0 to 40% EtOAc in Heptane
出典と根拠
- ORDレコード
- ord-a921f4fb3ed34a45a8254c55a38f3d89
- 出典データセット
- uspto-grants-2016_09
- 特許番号
- US09434725B2
関連ノート
読み込み中…